The pertinent question is the cost to bring this to commercialisation; you would envisage that it would be quite substantial; another 300 million US dollars plus, and that may well be quite understating, …..any delay to the 2028 commercialisation date will only blow that figure out further yet.
The comparison between Edwardes LS and this Co on R&D spend is graphic; how the heck does 100 mill US compete against 1 billion US dollars per year.
As per usual the IP is well highlighted, what is kept well under wraps are the hurdles bringing this to commercialisation, the costings the elephant in the room.
You would also have to wonder if the end date is set in concrete ( with this Co’s poor history in any of its forecasts) and the impact of a languishing sp on the 2028 finish line.
Be a great day when these sp sensitive Ann’s positively impact the sp, they do though keep the story alive to attract entities to do their thing regardless of whether the Co will succeed or not in the long run.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)